https://www.selleckchem.com/ph....armacological_epigen
Although Lp(a) contributes to the development of cardiovascular disease in patients with diabetes, few trials have investigated the benefits of reducing Lp(a) within this patient population. Furthermore, guidelines do not specifically address the risk associated with elevated Lp(a) levels. Despite this, Lp(a) should be measured in patients with diabetes and considered when evaluating their overall risk burden. This review summarizes the evidence that apolipoprotein B (apo integrates the conventional lipid markers - total ch
Me gusta
Comentario
Compartir
